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1. In December 2012, the Council adopted the EU Drugs Strategy for 2013-2020. Subsequently, 
the Irish Presidency prepared a draft proposal for a new EU Action Plan on Drugs (2013-
2016) which was examined during the HDG meetings on 9 January 2013, 6 February 2013, 
25 February 2013, 18 April 2013 and finalised at the HDG meeting on 23 May 2013. 
 
2. COREPER is therefore requested to invite the Council to adopt the draft EU Action Plan 
on Drugs as set out in annex. 
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Introduction 
 
The use of illicit drugs and the misuse of drugs generally, is a major problem for individuals, 
families and communities across Europe. Apart from the health and social implications of drug 
misuse, the illicit drugs market constitutes a major element of criminal activity across European 
society and, indeed, on a global level. 
 
In December 2012, the Council adopted the EU Drugs Strategy for 2013-2020. The Strategy aims to 
contribute to a reduction in drug demand and drug supply within the EU. It also aims to reduce the 
health and social risks and harms caused by drugs through a strategic approach that supports and 
complements national policies, that provides a framework for coordinated and joint actions and that 
forms the basis and political framework for EU external cooperation in this field. This will be 
achieved through an integrated, balanced and evidence-based approach. 
 
The objectives of the Strategy are: 
• to contribute to a measurable reduction of the use of drugs, of drug dependence and of drug-
related health and social risks and harms; 
• to contribute to a disruption of the illicit drugs market and a measurable reduction of the 
availability of illicit drugs; 
• to encourage coordination through active discourse and analysis of developments and 
challenges in the field of drugs at EU and international level; 
• to further strengthen dialogue and cooperation between the EU and third countries, 
international organisations and fora on drug issues; 
• to contribute to a better understanding of all aspects of the drugs phenomenon and of the 
impact of interventions in order to provide a sound and comprehensive evidence-base for 
policies and actions. 
 
This EU Drugs Action Plan, like the EU Drugs Strategy, is based on the fundamental principles of 
EU law and it upholds the founding values of the Union – respect for human dignity, liberty, 
democracy, equality, solidarity, the rule of law and human rights. It is also based on the UN 
Conventions that provide the international legal framework to address, inter alia, the use of illicit 
drugs, as well as on the Universal Declaration on Human Rights. 
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The Plan sets out the Actions that will be implemented to achieve the objectives of the Strategy. 
Actions are set out under the two policy areas of the Strategy: 
 
• Drug Demand Reduction; and 
• Drug Supply Reduction; 
 
and the three cross-cutting themes of the Strategy: 
• Coordination; 
• International Cooperation; and 
• Information, Research, Monitoring and Evaluation. 
 
Actions are aligned to objectives of the EU Drugs Strategy 2013-2020. In drawing up the actions, 
account was taken of the need to be evidence-based, scientifically sound, realistic, time-bound and 
measurable with a clear EU relevance and added value. This Action Plan indicates timetables, 
responsible parties, indicators and data collection/assessment mechanisms. 
 
Based on existing reporting mechanisms, a number of over-arching indicators are set out in Annex 
1. These facilitate the measurement of the overall effectiveness of this EU Drugs Action Plan and 
do not involve an additional reporting burden. A number of these are referenced, as appropriate, 
across the Plan. Furthermore, throughout the Plan, indicators are set out that draw on programme, 
evaluative and other data sources. Utilisation of these indicators is dependent on data collection 
processes in each Member State or at EU institution level. 
 
In line with the Strategy stipulation that its detailed implementation should be set out in two 
consecutive Action Plans, this Action Plan covers the four years from 2013 until 2016. A second 
Action Plan for the period 2017-20 will be prepared following an external mid-term assessment of 
the EU Drugs Strategy by 2016 and taking account of any other relevant strategies and evaluations. 
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1. Drug demand reduction 
 
Contribute to a measurable reduction in the use of illicit drugs, in problem drug use, in drug dependence and in drug-related health and social harms as 
well as contributing to a delay in the onset of drug use 
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
 
1. Improve the availability and 
effectiveness of prevention 
measures that take account of: 
(a) population risk factors such as 
age; gender; cultural and social 
factors;  
(b) situational risk factors such as 
homelessness; drug use in 
nightlife and recreational 
settings; the workplace; and 
driving under the influence of 
drugs; and 
(c) individual risk factors such as 
mental health; problem 
behaviour and psychosocial 
development; and other factors 
known to affect individual 
vulnerability to drug use such 
as genetic influences and 
family circumstances  
 
 
Ongoing MS o Overarching indicators 1, 12 
 
• Level of provision at MS level of evidence-
based universal and environmental prevention 
measures  
• Level of provision at MS level of targeted 
prevention measures, including family and 
community based measures 
• Level of provision at MS level of indicated 
prevention measures 
 
 
EMCDDA 
Reporting 
 
Reitox 
National 
Reports 
 
MS reporting 
on results of 
measures 
 
 
 
 
1. Prevent drug 
use and, 
secondly, delay 
the onset of 
drug use 
2. In addition to the prevention 
of drug use, strengthen and 
Ongoing  MS o Overarching indicators 1, 5, 12 
 
EMCDDA 
Reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
 
better target prevention and 
diversionary measures to delay 
the age of first use of illicit 
drugs 
 
• Level of provision at MS level of evidence 
based prevention and diversionary measures 
that target young people in family, 
community, and formal/non-formal education 
settings 
 
 
 
MS reporting 
on results of 
measures 
3. Raise awareness of the risks 
and  
consequences associated with 
the use of illicit drugs and 
other psychoactive substances 
Ongoing MS 
COM 
EMCDDA 
 
o Overarching indicators 5, 12 
 
• Level of awareness in general and youth 
populations of healthy lifestyles and of the 
risks and consequences of the use of illicit 
drugs and other psychoactive substances  
 
 
 
EMCDDA 
Reporting 
 
Eurobaro-
meter 
Surveys 
 
ESPAD 
 
HBSC 
 
 4. Enable a more informed 
response to the challenge of 
the misuse of prescribed and 
‘over the counter’ opioids and 
other psychoactive medicines  
 
 
2014-2016 MS 
HDG 
EMA 
EMCDDA 
 
• Collation of data by MS on levels and patterns 
of prescribing of psychoactive medicines by 
end 2014 
• Number of initiatives that focus on the 
promotion of appropriate use of prescribed and 
‘over the counter’ opioids and other 
psychoactive medicines  
 
 
MS 
Reporting 
 
Report of 
Alice RAP 
project 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
 
5. Develop and expand the 
diversity, availability, 
coverage and accessibility of 
comprehensive and integrated 
treatment services including 
those which address polydrug 
use (combined use of illicit 
and/or licit substances 
including alcohol) 
Ongoing MS o Overarching indicators 1, 6, 11 
 
 
• Extent of the diversity of comprehensive and 
integrated treatment services at MS level 
including those which address polydrug use 
• MS data on treatment retention and outcomes 
 
 
EMCDDA 
Reporting   
 
Reitox  
National 
Reports 
 
EMCDDA 
Best Practice 
Portal 
2. Enhance the 
effectiveness of 
drug treatment and 
rehabilitation, 
including services 
for people with co-
morbidity, to 
reduce the use of 
illicit drugs; 
problem drug use; 
the incidence of 
drug dependency 
and drug-related 
health and social 
risks and harms 
and to support the 
recovery and social 
re/integration of 
problematic and 
dependent drug 
users  
6. Expand the provision of   
rehabilitation/recovery 
services with an emphasis on 
services that: 
(a)   focus on providing a 
       continuum of care through  
       case management and  
       interagency collaboration for     
       individuals;  
      (b)   focus on supporting the  
             social re/integration  
             (including the 
             employability) of 
             problem and dependent drug  
             users; and 
      (c)   strengthen the diagnostic  
             process and the treatment of     
             psychiatric and physical co-    
             morbidity involving drug use 
 
Ongoing MS o Overarching indicator 11 
 
MS data on: 
• Extent of increase in rehabilitation/recovery 
services adopting case management and inter-
agency approaches 
• Extent of increase in the number of 
programmes, specifically targeted at drug 
users with co-morbidity, involving 
partnerships between both mental health and 
drug rehabilitation/ recovery services 
• Level and duration of abstentions from 
consumption of illicit and/or licit drugs by 
people leaving drug treatment 
• Availability of treatment options to meet needs 
of people who experience relapses to drug use 
 
 
 
EMCDDA 
Reporting 
 
MS 
Reporting on  
results of 
services  
 
 
  
9963/13  JV/dk 8 
ANNEX DG D 2C   E 
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
 
7. Ensure that treatment and 
outreach services incorporate 
greater access to risk and harm 
reduction options to lessen the 
negative consequences of drug 
use and to substantially reduce 
the number of direct and 
indirect drug-related deaths 
and infectious blood borne 
diseases associated with drug 
use but not limited to HIV and 
viral hepatitis, as well as 
sexually transmittable diseases 
and tuberculosis 
 
Ongoing MS 
 
o Overarching indicators 2, 3, 4, 11 
 
• Extent of increased availability of and access 
to evidence based risk and harm reduction 
measures in MS 
 
 
EMCDDA 
Reporting  
 
Reitox 
National 
Reports 
 
MS 
Reporting on 
services  
 
 
8. Scale up the development, 
availability and coverage of 
health care measures for drug 
users in prison and after 
release with the aim of 
achieving a quality of care 
equivalent to that provided in 
the community 
 
 
 
Ongoing MS o Overarching indicator 10 
 
• Availability of services for drug users in 
prisons and the extent to which prison health 
care policies and practices incorporate care 
models comprising best practices in needs 
assessment and continuity of care for prisoners 
during imprisonment 
• Extent of decrease in drug-related physical and 
mental health problems amongst prisoners 
• Extent to which prison based services and 
community based services provide continuity 
of care for prisoners upon release with 
particular emphasis on avoiding drug 
overdoses 
 
EMCDDA 
Reporting 
 
Reitox 
National 
Reports 
 
 
MS 
Reporting on 
services  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
 
3. Embed co-
ordinated, best 
practice and quality 
approaches in drug 
demand reduction  
9. Agree and commence the 
implementation of EU 
minimum quality standards, 
that help bridge the gap 
between science and practice, 
for:  
(a)  environmental, universal,  
       selective and indicated  
       prevention measures; 
(b)  early detection and 
       intervention measures;  
(c)  risk and harm reduction 
       measures; and  
(d)  treatment, rehabilitation, 
       social integration and recovery    
       measures 
 
2014-2016 Council  
HDG 
MS 
COM 
EMCDDA 
• Consensus achieved by MS on minimum 
quality standards building on previous EU 
preparatory studies 
 
 
EMCDDA 
Best Practice 
Portal 
 
COM 
Biennial 
Progress 
Report 
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2. Drug supply reduction 
 
Contribute to a measurable reduction of the availability and supply of illicit drugs in the EU 
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
10. Utilise to best effect available 
intelligence and information 
sharing law enforcement 
instruments, channels and 
communication tools used to 
collate and analyse drug-
related information  
 
Ongoing MS 
Europol 
Eurojust 
COSI 
 
o Overarching indicator 7 
 
 
• Extent of high impact intelligence led and 
targeted activities, of joint operations, joint 
investigation teams and cross border 
cooperation initiatives focusing on criminal 
organisations engaged in illicit drug activity 
• Increased use of Europol’s drug-related 
information-sharing, analysis and expert 
systems  
• Results achieved from EMPACT projects 
and bilateral and multilateral initiatives 
 
 
EMCDDA 
Reporting 
 
EU Agencies 
Reporting  
 
EMPACT 
Driver 
Reports 
 
 
4. Enhance 
effective law 
enforcement co-
ordination and co-
operation within 
the EU to counter 
illicit drug activity, 
in coherence, as 
appropriate, with 
relevant actions 
determined through 
the EU policy 
cycle  
11. Identify and prioritise the most 
pressing threats associated 
with drug-related organised 
crime 
 
 
 
 
2014 Council 
COSI 
Europol 
MS 
COM 
 
• EU Policy Cycle and Crime priorities for 
2014-2017 in place 
 
Council 
Conclusions 
on EU Policy 
Cycle 
 
EU SOCTA 
 
EMPACT 
Evaluation 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
12. Strengthen CEPOL’s training 
for law enforcement officers in 
relation to illicit drug 
production and trafficking, 
particularly training methods 
and techniques  
(a) to combat the use of new 
communication technologies 
in illicit drug production and 
trafficking;  
      (b) to enhance asset            
      confiscation;                                                
      (c) to combat money 
laundering;      
      and (d) to detect and dismantle    
      illicit clandestine laboratories             
      and cannabis cultivation sites  
2014 
 
2016  
MS 
CEPOL 
Europol 
COSI  
COM 
• Training needs assessment carried out by end 
2014  
• Availability and uptake of relevant training 
courses  
• Number of law enforcement officers trained 
and effectively deployed as a result 
 
COM 
Biennial 
Progress  
Report 
 
CEPOL 
Annual 
Report  
 
CEPOL 
Curricula  
 
EMPACT 
Evaluation  
 13. Improve counter narcotic 
activities through 
strengthening and monitoring 
the effectiveness of regional 
information-sharing platforms 
and regional security-sharing 
platforms with the aim of 
disrupting and suppressing 
emerging threats from 
changing drug trafficking 
routes 
Ongoing COM 
MS 
Europol 
 
COSI  
 
Regional 
Information-  
Sharing 
Platforms 
 
Regional 
Security-
Sharing 
Platforms 
o Overarching indicator 7 
 
• Number of intelligence led activities leading to 
the disruption and suppression of drug 
trafficking routes  
• Level of information sharing through effective 
activity of the liaison officer network 
 
EMCDDA 
Reporting 
 
Security/ 
Information -
sharing 
Platforms 
and 
Evaluation 
Reports 
 
EU SOCTA  
 
EMPACT 
Evaluation  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
14. Strengthen actions to prevent 
the diversion of drug 
precursors and pre-precursors 
for use in the illicit 
manufacture of drugs 
Ongoing MS 
Europol 
COM 
CUG 
COSI 
 
• Number of cases and quantity of stopped or 
seized shipments of precursors intended for 
illicit use 
• Results achieved from EMPACT projects 
• Use of Pre-Export Notification (PEN) Online 
System and increased use of the Precursors 
Incident Communication System (PICS) 
• Number of joint follow up meetings and other 
activities linked to the prevention of the 
diversion of precursors and pre-precursors 
 
Reports from 
EU and MS 
Law 
Enforcement 
Agencies 
 
EMPACT 
Evaluation  
Driver 
Reports 
 
15. Counter cross-border drug 
trafficking and improve border 
security notably at EU 
seaports, airports and land 
border crossing points through 
intensified efforts, including 
information and intelligence 
sharing, by relevant law 
enforcement agencies  
 
 
Ongoing MS 
Europol 
CCWP 
COSI 
 
• Increased number of multi-disciplinary/multi-
agency joint operations and cross border 
cooperation initiatives  
• Number of effective Memoranda of 
Understanding (MOU) agreed between law 
enforcement agencies and relevant bodies such 
as airlines, air express couriers, shipping 
companies, harbour authorities and chemical 
companies 
• Results achieved from EMPACT projects 
• Improved intelligence and information sharing 
on cross-border drug trafficking utilising, inter 
alia, available border surveillance systems 
 
airports and land border crossing points 
COM 
Biennial 
Progress  
Report 
 
EMPACT 
Evaluation 
and Driver 
Reports 
 
MS 
Reporting 
 
16. Develop and progressively 
implement key indicators on 
drug supply by standardising, 
improving and streamlining  
data collection in this field, 
building on currently available 
2013-2016 
 
 
 
 
 
COM 
MS 
Council 
HDG 
EMCDDA 
Europol 
• Roadmap developed and agreed on the 
implementation of key drug supply indicators 
• MS agreement reached on key drug supply 
indicators  
 
Overview of 
existing 
supply data 
collection in 
MS 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
data   
 
 
 
 
 
 
EMCDDA 
Reporting 
 
COM 
Biennial 
Progress 
Report 
 
17. Strengthen EU judicial co-
operation in targeting cross-
border drug trafficking, money 
laundering, and in the 
confiscation of the proceeds of 
drug-related organised crime 
 
2013-2016 
 
Council 
COM 
MS 
Eurojust 
 
• Adoption and timely implementation of agreed 
EU measures and legislation on                      
(a) confiscation and recovery of criminal 
assets; (b) money laundering; (c) 
approximation of drug trafficking offences and 
sanctions across the EU 
• Increased number of financial investigations 
and confiscations in relation to the proceeds of 
drug-related organised crime through EU 
judicial cooperation 
• Timely and effective responses to mutual 
assistance requests and European Arrest 
Warrants in relation to illicit drug trafficking     
Eurojust 
Reporting 
 
 
COM 
Biennial 
Progress 
Report  
 
 
 
 
 
5. Enhance 
effective judicial 
co-operation and 
legislation within 
the EU 
18. Introduce and adopt  new EU 
legislative measures to address the 
emergence, use and rapid spread 
of new psychoactive substances 
 
2013-2016 COM 
Council 
HDG 
MS 
• EU legislation in place  
• Implementation of EU legislation in MS  
 
COM 
Biennial 
Progress 
Report  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
19. Strengthen EU legislation on drug 
precursors to prevent their 
diversion without disrupting 
lawful trade 
Ongoing Council 
COM 
MS 
• Adoption and implementation of Regulations 
of the European Parliament and of the Council 
on drug precursors amending both Council 
Regulation (EC) No. 111/2005 and  
Regulation (EC) No. 273/2004  
COM 
Biennial 
Progress 
Report  
EU Annual 
Report on 
Drug 
Precursors 
20. Combat the use of certain 
pharmacologically active 
substances (as defined in EU 
Directive 2011/62) as cutting 
agents for illicit drugs 
Ongoing MS 
COM 
EMA 
EMCDDA 
Europol 
• Number of seizures of active substances used 
as cutting agents for illicit drugs 
• Timely implementation of new EU legislative 
requirements aimed at securing the supply 
chain for active substances under Directive 
2011/62/EU, the Falsified Medicines Directive 
Reports from 
the CCWP 
and CUG 
 
MS 
Reporting 
 21. Members States to provide, where 
appropriate and in accordance 
with their legal frameworks, 
alternatives to coercive sanctions 
(such as education, treatment, 
rehabilitation, aftercare and social 
integration) for drug using 
offenders 
 
 
 
2015 MS 
 
• Increased availability and implementation of 
alternatives to prison for drug-using offenders 
in the areas of education, treatment, 
rehabilitation, aftercare and social integration 
• Increased monitoring, implementation and 
evaluation of alternatives to coercive sanctions  
 
Reitox 
National 
Reports 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
6.  Respond 
effectively to 
current and 
emerging trends 
in illicit drug 
activity 
 
 
22. Identify strategic responses to 
address the role of new 
communication technologies and 
the hosting of associated websites, 
in the production, marketing, 
purchasing and distribution of 
illicit drugs, including controlled 
new psychoactive substances 
 
Ongoing Council 
COM 
HDG 
MS 
Europol 
COSI 
 
• Results achieved from law enforcement 
actions targeting drug-related crime via the 
internet  
• Increased number of joint operations and    
cross border cooperation initiatives 
Progress 
Review of 
EU Policy 
Cycle 
Priorities 
 
EMPACT 
Evaluation 
and  
Driver 
Reports 
 
MS 
Reporting 
 
Reports from 
EU Agencies 
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3. Co-ordination 
 
Member States and EU to effectively co-ordinate drugs policy 
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
23. Enhance information sharing between 
the HDG and other relevant Council 
Working Groups 
Ongoing PRES 
Council 
EEAS 
HDG 
 
• Extent to which the EU Drugs 
Strategy/and Action Plan are taken into 
account in the Programmes of other 
Council Working Groups  including 
COAFR, COASI, COEST, COLAT and 
COWEB 
Council 
Working 
Group 
reporting  
 
24. Each Presidency may convene 
meetings of the National Drugs Co-
ordinators, and of other groupings as 
appropriate, to consider emerging 
trends, effective interventions and 
other policy developments of added 
value to the EU Drugs Strategy and to 
MS  
Biannually PRES 
MS 
 
• Extent to which National Drug Co-
ordinators’ meeting agenda reflects 
developments, trends and new insights in 
policy responses and provides for 
improved communication and 
information exchange 
 
Presidency 
Reporting 
25. The HDG will facilitate (a) monitoring 
of the implementation of the Action 
Plan through thematic debates; and (b)  
an annual dialogue on the state of the 
drugs phenomenon in Europe 
(a) 
Biannually 
 
(b) 
Annually 
PRES 
HDG 
MS 
COM 
EMCDDA 
Europol 
• Extent of implementation of the Action 
Plan 
• Timeliness of dialogue at the HDG on 
latest drug-related trends and data 
 
Presidency 
Reporting 
 
 
 
 
 
7. Ensure effective 
EU co-ordination 
in the drugs field 
26. Ensure consistency and continuity of 
MS and EU actions across Presidencies 
to strengthen the integrated, balanced 
and evidence-based approach to drugs 
in the EU  
Biannually PRES 
PRES Trio 
MS 
COM 
HDG 
EMCDDA 
Europol 
 
• Extent of consistency and continuity of 
actions across Presidencies 
• Advancement in implementation of EU 
Drugs Strategy priorities across 
Presidencies 
 
Presidency 
Reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
 
27. Ensure co-ordination of EU drugs 
policies and responses, to support 
international co-operation between the 
EU, third countries and international 
organisations   
Ongoing EEAS 
COM 
HDG 
MS 
 
•  Level of consistency and coherence in 
the objectives, expected results and 
measures foreseen in EU actions on 
drugs 
•  Inclusion of drug-related priorities in 
strategies of relevant EU bodies 
•  Intensified co-operation between the 
HDG and the geographical/regional 
working groups, including COAFR, 
COASI, COEST, COLAT and COWEB 
 
Annual 
EEAS Report 
to the HDG 
 
COM 
Biennial 
Progress 
Report 
 28. Achieve a co-ordinated and appropriate 
level of resources at EU level and 
Member State level to fulfil the 
priorities of the EU Drugs Strategy 
 
 
Annually MS 
COM 
EEAS 
Council 
HDG 
o Overarching indicator 14 
 
• Amount of funding at EU level, and 
where appropriate, MS level 
•  Extent of co-ordination on drugs-related 
financial programmes across Council 
Working Groups 
 
EMCDDA 
Reporting 
 
COM 
Biennial 
Progress 
Report   
8. Ensure effective 
co-ordination of 
drug-related policy 
at national level  
29. Co-ordinate actions on drugs policy 
between Government 
Departments/Ministries and relevant 
agencies at MS level and ensure 
appropriate multi-disciplinary 
representation on, or input to, HDG 
delegations 
Ongoing MS 
 
o Overarching indicator 14 
 
• Effectiveness of a horizontal drug policy 
co-ordination mechanism at MS level 
• Number of cross-cutting actions in drug 
demand and supply reduction at Member 
State level 
 
EMCDDA 
Reporting 
 
Reitox 
National 
Reporting 
 
COM Biennial 
Progress 
Report  
 
MS Reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
9. Ensure the 
participation of 
civil society  in 
drugs policy 
30. Promote and support dialogue with, and 
involvement of, civil society and the 
scientific community in the 
development and implementation of 
drugs policies at MS and EU levels 
Ongoing MS 
COM 
HDG 
PRES 
 
• Timely dialogues between EU Civil 
Society Forum on Drugs and  the HDG 
during each Presidency period 
 
• Engagement of EU Civil Society Forum 
in reviewing implementation of the EU 
Drugs Action Plan 
 
• Level of involvement of civil society in 
MS and EU drugs policy development 
and implementation with particular regard 
to the involvement of drug users, clients 
of drug-related services and young people 
 
• Timely dialogue between the scientific 
community (natural and social sciences, 
including neuroscience and behavioural 
research) and the HDG 
 
 
 
COM 
Biennial  
Progress 
Report 
 
Feedback  
from EU 
Civil Society 
Forum on 
Drugs and 
from Civil 
Society 
Representa-
tives at MS 
level 
 
MS 
Reporting 
 
Feedback 
from 
Scientific 
Community 
through the 
EMCDDA 
Scientific 
Committee 
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4. International Co-operation 
 
Strengthen dialogue and cooperation between the EU and third countries and international organisations on drugs issues in a comprehensive 
and balanced manner  
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
31.  Ensure policy coherence between the 
internal and external aspects of the EU 
drugs policies and fully integrate drugs 
issues within the political dialogues and 
framework agreements between the EU and 
its partners and in the EU advocacy on 
global issues or challenges 
 
 
 
Ongoing COM 
EEAS  
PRES  
HDG 
MS 
 
o Overarching indicator 13 
 
• Drug policy priorities 
increasingly reflected in EU’s 
external policies and actions 
• Inclusion of drug-related 
priorities in EU strategies with 
third countries and regions 
• Number of agreements, strategy 
papers, action plans in place 
 
EEAS 
Reporting  
 
Mid-Term 
Review of 
EU Drugs 
Strategy  
 
COM 
Biennial 
Progress 
Report  
10. Integrate the EU 
Drugs Strategy 
within the EU's 
overall foreign 
policy framework as 
part of a 
comprehensive 
approach that makes 
full use of the 
variety of policies 
and diplomatic, 
political and 
financial instruments 
at the EU's disposal 
in a coherent and co-
ordinated manner 
32. Ensure that the policy priorities and the 
balance between demand and supply 
reduction are well reflected in policy 
options and in the programming and 
implementation of external assistance, 
particularly in source and transit countries, 
through projects involving: 
(a)  development of integrated,  balanced and  
      evidence-based drug policies; 
(b)  supply reduction; 
(c)  the prevention of the diversion of drug  
      precursors and pre-precursors; 
(d)  drug demand reduction; and  
(e)  alternative development measures  
 
Ongoing COM 
MS 
EEAS 
• Extent to which EU’s Drug 
policy priorities, especially the 
balance between demand and 
supply reduction, are reflected 
in funded priorities and projects 
• Level of implementation of co-
ordinated actions in action plans 
between the EU and third 
countries and regions 
• Number of third country 
national strategies and action 
plans that incorporate integrated 
drug policies 
COM 
Biennial 
Progress 
Report  
 
 
EEAS 
Reporting on 
Programm-
ing 
 
Monitoring 
and 
Evaluation 
by MS 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
33. Improve capacity and strengthen the role of 
EU Delegations to enable them to 
proactively engage on drugs policy issues 
2013-2016 EEAS 
COM 
MS 
• Relevant expertise, training and 
policy guidance provided to EU 
Delegations 
• Regional networking among EU 
Delegations on drug issues 
enhanced 
• Co-ordination with MS 
enhanced 
 
EEAS 
Reporting on  
EU 
Delegations  
34. Ensure an appropriate level of EU and MS 
funding and expertise to further strengthen 
and support third countries' efforts in 
addressing and preventing illicit drug crop 
cultivation, through rural development 
measures, in order to deal with the 
challenges to public health, safety and 
security  
 
 
Ongoing MS 
EEAS 
COM 
• Number of third country 
national policies, strategies and 
action plans that incorporate 
integrated approaches to the 
problem of illicit drug crop 
cultivation 
• Improvements in human 
development indicators in drug-
cultivating areas 
• Number of rural development 
projects and programmes, 
funded by the EU and MS in 
regions where illicit crop 
cultivation is taking place, or in 
regions at risk of illicit crop 
cultivation   
• Reported local decrease in illicit 
drug crop cultivation in the 
long-term 
 
 
EU and MS 
Project and 
Programme 
Monitoring 
and 
Evaluation 
Systems and 
Reports 
 
UNDP 
Human 
Development 
Reports 
 
Third 
country 
reports  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
35. Promote and implement the EU approach to 
alternative development (consistent with the 
EU Drugs Strategy 2013-2020; the EU 
Approach to Alternative Development and 
the United Nations Guiding Principles on 
Alternative Development 2013) in co-
operation with third countries, taking into 
account human rights, human security and 
specific framework conditions, including: 
(a)  incorporating alternative development into 
        the broader agenda of Member States, 
       encouraging third countries that wish to do 
       so to integrate alternative development into 
       their national strategies; 
(b)  contributing to initiatives that aim to 
       reduce poverty, conflict and vulnerability 
       by supporting sustainable, legal and gender 
       sensitive livelihoods for people who were 
       previously, or are currently, involved in 
       illicit drug  production 
Ongoing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MS 
COM 
EEAS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Number of third country national 
policies, strategies and action 
plans that incorporate:  
o integrated approaches to 
the problem of illicit 
drug cultivation and  
o effectively organised 
alternative development 
initiatives  
• Number of evaluated projects 
that demonstrate positive 
outcomes relating to 
sustainable, legal and gender 
sensitive livelihoods 
• Improvements in human 
development indicators 
 
 
 
 
 
 
Third 
countries’ 
implementa-
tion reports 
of National 
Drugs 
Strategies 
 
 
EU and MS 
Project and 
Programme 
Monitoring 
and 
Evaluation 
system and 
Report 
 
UNDP 
Human 
Develop-
ment Reports 
36. Support third countries, including civil 
society in those countries, to develop and 
implement risk and harm reduction 
initiatives particularly where there is a 
growing threat of transmission of drug-
related blood borne viruses associated with 
drug use including but not limited to HIV 
and viral hepatitis, as well as sexually 
transmittable diseases and tuberculosis 
Ongoing MS 
COM 
EEAS 
 
 
• Number and quality of risk and 
harm reduction initiatives 
developed 
• Prevalence of drug-related 
deaths in third countries  and 
drug-related blood borne viruses 
including but not limited to HIV 
and viral hepatitis, as well as 
sexually transmittable diseases 
and tuberculosis  
Third country 
Reports 
 
COM Biennial 
Progress 
Report 
 
WHO Reports  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
37. Support third countries to tackle drug-
related organised crime, including drug 
trafficking, by: 
(a)  intelligence-sharing and the exchange of  
      best practices; 
(b)  strengthening counter-narcotics capacity     
      and developing expertise of source and  
      transit countries;  
(c)  working with international partners to tackle  
      the enablers of drug trafficking such as  
      corruption, weak institutions, poor  
      governance and lack of financial regulatory  
      controls;  
(d)  strengthening co-operation in the field of  
      asset identification and recovery, in     
      particular through the creation of    
      dedicated national platforms; and 
(e)  intensifying regional and intra-regional co-    
      operation 
Ongoing 
 
MS 
EEAS 
COM 
Europol 
 
• Number and effectiveness of 
projects and programmes 
• Sustained reduction in drug 
trafficking  
COM 
Biennial 
Progress 
Report 
 
MS 
Reporting  
 
Europol 
Reporting 
 
EEAS 
Reporting 
 
UNODC 
Annual 
World Drug 
Report 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
38. Reinforce co-operation and update and 
implement Dialogues, Declarations and EU 
Drugs Action Plans with partners, 
including: 
(a)  Acceding countries, candidate countries and 
potential candidates 
(b)  European Neighbourhood Policy countries 
(c)  United States of America, the   
       Russian Federation 
(d)  Other countries or regions of priority 
notably: 
• Afghanistan and Pakistan  
• Central Asian Republics 
• China 
• Latin American and the Caribbean 
(CELAC) 
• Africa, in particular West Africa 
 
Ongoing PRES Trio 
COM 
EEAS 
MS 
 
 
 
o Overarching indicator 13 
 
• Strengthened co-operation in 
the field of drugs with relevant 
partners  
• Dialogues organised 
• Declarations agreed  
• Programmes and Action Plans 
implemented 
 
 
EEAS 
Reporting 
 
Mid-Term 
Review of 
EU Drugs 
Strategy 
 
 
COM 
Biennial 
Progress 
Report  
 
EU 
Reporting 
Matrices  
 
Implementa-
tion Reports 
of the 
relevant 
action plans  
 
39. Improve the Dublin Group consultative 
mechanism through intensified EU 
coordination and participation, better 
implementation and dissemination of the 
recommendations of the Mini Dublin Group 
reports 
Ongoing Dublin Group 
COM 
EEAS 
MS 
• Level of activity across Dublin 
Group structures including 
number of Dublin Group 
recommendations effectively 
implemented 
 
Dublin 
Group 
Reports 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
40. Hold an annual dialogue on EU and MS 
drugs-related assistance to third countries 
accompanied by a written update  
 
 
 
From 
2014  
 
COM 
EEAS 
MS 
 
• Annual dialogue on funding 
held  
 
COM  
Biennial 
Progress 
Report   
 
MS 
Reporting 
 
EEAS 
Reporting 
 
Project and 
Programme 
Monitoring 
and 
Evaluation 
System and 
Reports 
41. Ensure that the promotion and protection of 
human rights are fully integrated in political 
dialogues and in the planning and 
implementation of relevant drugs-related 
programmes and projects including through 
the development of a human rights guidance 
and impact assessment tool  
 
Ongoing COM 
EEAS 
MS 
• Human rights effectively 
mainstreamed into EU external 
drugs action 
• Human rights guidance and 
assessment tool developed and 
implemented 
 
 
 
 
 
 
 
 
COM 
Biennial 
Progress 
Report 
 
COHOM 
Annual 
Human 
Rights 
Report 
 
MS 
Reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
12. Improve 
cohesiveness of EU 
approach and EU 
visibility  in the 
United Nations (UN) 
and strengthen EU 
co-ordination with 
international bodies 
related to the drugs 
field 
42. Contribute to shaping the agenda on 
international drugs policy, including 
through:  
(a)  action by EU and MS Delegations at the     
       UN General Assembly and the Commission  
      on Narcotic Drugs (CND); 
(b)  preparation, co-ordination and adoption of  
       EU common positions and joint resolutions  
       in the UN General Assembly and the CND  
       and ensuring that the EU speaks with one  
       strong voice in these and other international   
      fora; 
(c)  the mid-term review process of the 2009  
      UN Political Declaration and Action Plan on  
      International Cooperation towards an  
       Integrated and Balanced Strategy to Counter  
      the World Drug Problem; and 
(d)  the 2016 UN General Assembly Special         
      Session on Drugs 
 
 
 
 
 
Ongoing EEAS 
PRES 
MS 
COM 
Council 
HDG 
o Overarching indicator 13 
• Effective promotion of EU 
policies in the UN, including at 
the CND 
• Number of EU common 
positions supported by other 
regions and international bodies 
• Frequency with which EU 
speaks with a single effective 
voice in international fora and 
in dialogues with third countries 
• Level of successful adoption  of 
EU resolutions at UN including 
at the CND 
• Outcome of the Mid-term 
Review of the 2009 UN 
Political Declaration and Action 
Plan on International Co-
operation towards an Integrated 
and Balanced Strategy to 
Counter the World Drug 
Problem 
• Adoption of an EU Joint 
Position Paper for the 2016 
UNGASS and reflection of the 
EU positions in the UNGASS 
outcome  
 
 
EEAS 
Reporting  
 
Mid-Term 
Review of 
the EU 
Drugs 
Strategy 
 
COM 
Biennial 
Progress 
Report  
 
Convergence 
Indicator  
 
Mid-term 
Review 
 
UNGASS 
Outcome 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
43. Strengthen partnerships with the UNODC, 
WHO UNAIDS and other relevant UN 
agencies, international and regional bodies 
and organisations and initiatives (such as 
the Council of Europe and the Paris Pact 
Initiative)  
Ongoing Council 
EEAS 
COM 
PRES 
HDG 
 
o Overarching indicator 13 
 
• Number of information 
exchanges and activities 
between the EU and relevant 
international and regional 
bodies and organisations and 
initiatives 
• Effectiveness of partnerships 
with relevant bodies 
EEAS 
Reporting  
 
Mid Term 
Review of 
the EU 
Drugs 
Strategy 
 
COM 
Biennial 
Progress 
Report  
 
13. Support the 
process for 
acceding 
countries, 
candidate 
countries, and 
potential 
candidates to 
adapt to and align 
with the EU 
acquis in the 
drugs field, 
through targeted 
assistance and 
monitoring 
44. Provide targeted technical assistance, and 
other assistance and support as necessary, to 
acceding countries, candidate countries, and 
potential candidates to facilitate their 
adaptation to and alignment with the EU 
acquis in the drugs field  
 
Ongoing COM 
MS 
EMCDDA 
Europol 
Eurojust 
FRONTEX 
EEAS 
• Increased compliance by 
countries with EU acquis 
• Number and quality of 
completed projects 
• National Drugs Strategies and 
national drugs co-ordinating 
structures established 
COM 
Biennial 
Progress  
Report  
 
Acceding 
countries, 
candidate 
countries and 
potential 
candidates 
reports 
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5. Information, research, monitoring and evaluation 
 
Contribute to a better understanding of all aspects of the drugs phenomenon problem and of the impact of measures in order to provide sound 
and comprehensive evidence for policies and actions 
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
14.  Ensure 
adequate 
investment in 
research, data 
collection, 
monitoring, 
evaluation and  
information 
exchange on 
all aspects of 
the drug 
phenomenon  
45. Promote appropriate financing of EU-level 
drug-related multi-disciplinary research and 
studies including through EU related 
financial programmes (2014-2020)  
 
 
2014-2016 MS 
COM 
EMCDDA 
 
• Amount and type of EU funding 
provided across the different 
programme and projects 
 
COM 
Biennial 
Progress 
Report  
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 46. Ensure that EU-supported projects:  
 
(a)  take account of the priorities of the     
      EU Drugs Strategy and Action Plan on    
      Drugs; 
(b)  take account of gaps in policy formulation; 
(c)  deliver clear added value and ensure      
      coherence and synergy; and  
(d)  avoid duplication with research under other  
      programmes and bodies 
(e)  take account of the importance of 
behavioural research and neuroscience  
 
 
2014-2016 COM 
EMCDDA 
• The inclusion of the priorities of the 
EU Strategy and Action Plan on 
Drugs in the funding and assessment 
criteria of EU-funded drugs related 
research  
• Number, impact, complementarity 
and value of EU-funded drugs 
related research grants and contracts 
awarded  
• Number of EU-funded drugs related 
articles and research reports 
published in peer-reviewed journals 
with high impact factors 
• Annual debate at the HDG on drug- 
related research projects funded by 
the EU 
 
COM Biennial 
Progress 
Report  
 
Research 
project reports 
 
EMCDDA 
Scientific 
Committee 
recommenda-
tions on 
research 
priorities 
 
Science 
Citation Index 
and similar 
bibliometric 
tools 
 
Strategic 
research 
agenda and 
projects 
stemming 
from the ERA-
net on drug  
demand and 
supply 
reduction  
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 47. Promote scientific evaluations of policies 
and interventions at national, EU and 
international level 
2013-2016 COM 
MS 
EMCDDA 
 
o Overarching indicator 14 
 
 
• Regular progress review to the 
Council and European Parliament 
on Strategy and Action Plan 
implementation 
 
• External mid-term assessment of the 
Strategy/Action Plan completed – 
2016 
 
 
• European guidelines for the 
evaluation of national drug strategies 
and action plans published 
 
• Delivery of dedicated studies into the 
effectiveness and impacts of EU and 
international drug policies 
 
• Completed evaluation of the 
implementation of the 2003 Council 
Recommendation on the prevention 
and reduction of health-related harm 
associated with drug dependence 
EMCDDA 
Reporting 
 
COM 
Biennial 
Progress 
Report  
 
Mid-term 
Assessment 
Report of EU 
Drugs 
Strategy 
 
EMCDDA 
Reporting  
 
EMCDDA 
Scientific 
Committee 
Reporting 
 
Reports of 
Alice RAP 
and 
LINKSCH 
and ERA-net   
 
Reitox 
National 
Reports 
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48. In collaboration with relevant parties as 
appropriate, continue to provide 
comprehensive analyses of:  
(a)  the EU drugs situation;                                     
(b)  the dynamics of drug use within general  
      populations and target groups; and 
(c)  responses to drug use 
 Ongoing   
 
 
 
 
 
 
EMCDDA 
Europol  
MS 
 
 
 
o Overarching indicators 1-15   
 
• Current deficits in the knowledge 
base established and an EU level 
framework developed to maximise 
analyses from current data holdings  
• Number of overviews and topic 
analyses on the drug situation 
EMCDDA 
Reporting 
 
MS 
Reporting 
 
15 Maintain 
networking and 
co-operation 
and develop 
capacity within 
and across the 
EU’s 
knowledge 
infrastructure 
for information, 
research, 
monitoring and 
evaluation of 
drugs, 
particularly 
illicit drugs 
49. Enhance training for those involved in 
responding to the drugs phenomenon 
2014-2016               MS 
EMCDDA 
CEPOL 
• Number of initiatives at MS and EU 
level to train professionals in aspects 
of drug demand reduction and drug 
supply reduction 
• Number of initiatives at MS and EU 
level implemented to train 
professionals  related to data 
collection and reporting of drug 
demand reduction and drug supply 
reduction 
MS 
Reporting 
 
EMCDDA 
Training 
Report 
 
CEPOL 
Annual 
Report 
 
Reitox 
Annual 
Reports 
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50. Enhance data collection, research, analysis 
and reporting  on:  
(a)  drug demand reduction;  
(b)  drug supply reduction;  
(c)  emerging trends, such as polydrug use and  
       misuse of prescribed controlled medicines,             
       that pose risks to health and safety;  
(d)  blood borne viruses associated with drug  
      use including but not limited to HIV and  
      viral hepatitis, as well as sexually  
      transmittable diseases and tuberculosis; 
(e)  psychiatric and physical co-morbidity;  
(f)  drug problems among prisoners and the  
      availability and coverage of drug demand  
      reduction interventions and services in  
      prison settings; and 
(g)  other drug-related consequences 
Ongoing MS 
COM 
EMCDDA 
Europol 
ECDC 
EMA 
  
• Increased availability and 
implementation of evidence-based 
and scientifically sound indicators on 
drug supply reduction and drug 
demand reduction 
• At MS level, extent of new research 
initiated on emerging trends such as 
polydrug use and the misuse of 
prescribed controlled medicines;  
blood borne diseases associated with 
drug use including but not limited to 
HIV and viral hepatitis, as well as 
sexually transmittable diseases and 
tuberculosis; psychiatric and 
physical co-morbidity; and other 
drug-related consequences 
• EU-wide study carried out on drug-
related community intimidation and 
its impact on individuals, families 
and communities most affected and 
effective responses to it 
• Adoption of evidence-based and 
scientifically sound indicators on  
drug problems among prisoners  
EMCDDA 
Reporting 
 
MS 
Reporting 
 
Harmonised 
data reports 
from EU 
bodies 
including 
EMCDDA 
 
 
 
EU SOCTA  
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51. Improve the capacity to detect, assess and 
respond effectively to the emergence and 
use of new psychoactive substances and 
monitor the extent to which such new 
substances impact on the number and 
profile of users 
 
 
 
Ongoing COM 
MS 
EMCDDA 
Europol 
 
o Overarching indicator 6 
 
• Extent of new epidemiological, 
pharmacological and toxicological 
research initiated on new 
psychoactive substances and 
supported by MS and EU Research 
programmes 
• Extent of information, best practice 
and intelligence exchange 
• Extent of sharing by toxicology 
laboratories and by Research 
Institutes of toxicological and health 
data analyses on new psychoactive 
substances 
 
EMCDDA 
Reporting 
 
EMCDDA-
Europol 
Implementati
on Report 
 
Reports by 
laboratories 
and research 
institutes 
 
Reitox 
National 
Reports  
52. Strengthen efforts to share forensic science 
data, including laboratory reference 
standards, on new psychoactive substances, 
by enhancing co-operation through existing 
networks, such as the Drugs Working 
Group of the European Network of Forensic 
Science Institutes in the framework of the 
JHA Council Conclusions on the Vision for 
European Forensic Science 2020  
2016 COM 
MS 
EMCDDA 
 
o Overarching indicator 15 
 
• Extent of sharing of forensic science 
data on new psychoactive substances  
• Ease of access to laboratory 
reference standards by forensic 
science laboratories and institutes 
 
 
EMCDDA/ 
Europol 
Reporting 
 
COM 
Biennial 
Progress 
Report 
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 53. Improve the ability to identify, assess and 
respond at MS and EU levels to  (a) 
behavioural changes in drug consumption 
and (b) to epidemic outbreaks 
Ongoing MS 
EMCDDA 
ECDC 
EMA 
• Number and effectiveness of new 
drug-related public health initiatives 
developed and implemented 
• Number and effectiveness of existing 
initiatives that are adjusted to take 
account of drug consumption or 
epidemic outbreaks 
• Number and impact of early warning 
reports, risk assessment and alerts 
Reitox 
National 
Reports 
 
Early 
Warning 
System 
reports 
 
EMCDDA 
Reporting 
 
 
16. Enhance 
dissemination of 
monitoring, 
research and 
evaluation results 
at EU and national 
level  
54. Member States continue to support EU 
monitoring and information exchange 
efforts, including co-operation with, and 
adequate support for, Reitox National Focal 
Points 
Ongoing MS 
 
EMCDDA 
• Open-access outputs from EU 
funded studies disseminated  
• Extent to which Reitox National 
Focal Points funding and other 
resources match requirements 
• Number and effectiveness of Reitox 
National Focal Points dissemination 
initiatives 
Web 
Dissemina-
tion 
including 
OpenAire, 
Cordis  
 
EMCDDA 
website  
 
Reitox 
National 
reports 
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Annex 1 
 
15 Over-arching Indicators for the EU Action Plan on Drugs 2013-2016 (existing reporting 
mechanisms) 
 
1. Percentage of population who use drugs currently (within last month), used drugs recently 
(within last year), and who have ever used (lifetime use) by drug and age group  (EMCDDA 
General Population Survey) 
2. Estimated trends in the prevalence of problem and injecting drug use (EMCDDA Problem 
Drug Use) 
3. Trends in drug induced deaths and mortality amongst drug users (according to national 
definitions)(EMCDDA Drug-related Deaths) 
4. Prevalence and incidence, among injecting drug users, of infectious diseases attributable to 
drug use, including HIV and viral Hepatitis, sexually transmittable diseases and tuberculosis  
(EMCDDA Drug-related Infectious Diseases) 
5. Trends in the age of first use of illicit drugs (European School Survey Project on Alcohol and 
Drugs (ESPAD), Health Behaviour in School-aged Children (HBSC) and General Population 
Drug Use Survey (EMCDDA Key Epidemiological Indicator)  
6. Trends in numbers of people entering drug treatment (EMCDDA Treatment Demand) and the 
estimated total number of people in drug treatment (EMCDDA Treatment Demand and 
Health and Social Responses) 
7. Trends in number of and quantities of seized illicit drugs (EMCDDA Drug Seizures: cannabis 
incl. herbal cannabis, heroin, cocaine, crack cocaine, amphetamine, methamphetamine,  
ecstasy, LSD and other substances) 
8. Trends in retail price and purity of illicit drugs (EMCDDA Price and Purity:  cannabis incl. 
herbal cannabis, heroin, cocaine, crack cocaine, amphetamine, methamphetamine, ecstasy, 
LSD, other substances and composition of drug tablets) 
9. Trends in the number of initial reports of drug law offences, by drug and type of offence 
(supply vs use/possession)(EMCDDA Drug Offences) 
10. Prevalence of drug use amongst prisoners (EMCDDA Drug Use in Prisons) 
  
9963/13 JV/dk 35 
ANNEX 1 DG D 2C   E 
 
11. Assessment of availability, coverage and quality of services and interventions in the areas of 
prevention, harm reduction, social integration and treatment. (EMCDDA Health and Social 
Responses) 
12. Evidence based interventions on prevention,  treatment, social integration and recovery and 
their expected impact on drug use prevalence and problem drug use (EMCDDA Best Practice 
Portal) 
13. Strong dialogue and co-operation, in the drugs related field, with other regions, third 
countries, international organisations and other parties (External Mid-Term Evaluation of 
Strategy/Action Plan; EEAS reporting) 
14. Developments in national drug strategies, evaluations, legislation, co-ordination mechanisms 
and public expenditure estimates in EU Member States (EMCDDA) 
15. Early Warning System on new psychoactive substances (EMCDDA/Europol)  
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Annex 2 
Glossary of Acronyms 
 
Alice RAP  Addiction and Lifestyles in Contemporary Europe Reframing Addictions Project 
ASEAN  Association of Southeast Asian Nations 
CCWP  Council of the EU - Customs Cooperation Working Party  
CELAC  Comunidad de Estados Latinoamericanos y Caribeños (Community of Latin 
American and Caribbean States) 
CEPOL  European Police College 
CICAD  La Comisión Interamericana para el Control del Abuso de Drogas (The Inter-
American Drug Abuse Control Commission) 
CND   Commission on Narcotic Drugs (UN)  
COAFR  Council of the EU - Africa Working Party 
COASI  Council of the EU - Asia-Oceania Working Party 
COEST  Council of the EU - Working Party on Eastern Europe and Central Asia 
COHOM  Council of the EU - Working Party on Human Rights 
COLAT  Council of the EU - Working Party on Latin America 
COM  European Union Commission 
COSI  Council of the EU - Standing Committee on Operational Cooperation on Internal 
Security  
COWEB  Council of the EU - Working Party on the Western Balkans Region 
CUG   Council of the EU - Customs Union Group 
ECDC  European Centre for Disease Control 
ECOWAS  Economic Community of West African States 
EEAS  European Union External Action Service 
EMA   European Medicines Agency 
EMCDDA  European Monitoring Centre for Drugs and Drug Addiction 
EMPACT   European Multidisciplinary Platform against Criminal Threats 
ENFSI  European Network of Forensic Science Institutes 
ERA-net  European Research Area - Network 
ESPAD  European School Survey Project on Alcohol and Drugs 
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EU SOCTA EU Serious and Organised Crime Threat Assessment 
FRONTEX European Agency for the Management of Operational Cooperation at the External 
Borders of the Member States of the European Union 
HBSC  Health Behaviour in School Aged Children survey 
HDG   Council of the EU - Horizontal Working Group on Drugs 
INCB  International Narcotics Control Board (UN) 
JHA   Justice and Home Affairs 
LINKSCH  The LINKSCH project is a comparative study of two major drug markets, 
cannabis and heroin, through the prism of the transit chains operating between 
Central Asia and the EU and those between North Africa and the EU 
MS   Member State 
PEN   UNODC/INCB developed Pre-Export Notification Online System 
PICS  Precursors Incident Communication System 
PRES  Rotating Presidency of the Council of the European Union 
PRES Trio  Grouping of three consecutive rotating Presidencies of the Council of the 
European Union 
Reitox  Réseau Européen d’Information sur les Drogues et les Toxicomanies 
SOCTA  Serious and Organised Crime Threat Assessment 
UN   United Nations 
UNAIDS  Joint United Nations Programme on HIV/AIDS 
UNGASS  United Nations General Assembly Special Session 
UNODC  United Nations Office on Drugs and Crime 
WCO  World Customs Organisation 
WHO  World Health Organisation (UN) 
 
 
________________________ 
